

## Inbal Zafir-Lavie, Bio



Dr. Zafir-Lavie completed her PhD in 2010 at the Technion, in antibody engineering and cancer immunology.

Upon completing her PhD, Dr. Zafir-Lavie worked at Bio-Rad R&D site. Next, Dr. Zafir-Lavie joined Aevi Genomic Medicine as a team leader for the development of the antibody gene-therapy platform and later as Head of Israel R&D Site. Later, she relocated to Philadelphia, PA USA to work as a Senior Scientist collaborating with the Center of Applied Genomics (CAG) at Children's Hospital of Philadelphia (CHOP). In her work in the USA, Dr. Zafir-Lavie developed innovative diagnostic assays and cutting-edge therapeutics for autoimmune diseases.

Upon returning from the USA, Dr. Zafir-Lavie worked for Merck group as a senior scientist where she was responsible for transferring innovative projects from the academy to the industry towards IND.

In 2020 Inbal joined Nevia Bio as CEO and co-founder. Inbal is leading Nevia Bio to develop a Machine-Learning enabled home-use platform for early detection of ovarian cancer and additional women related diseases.

Inbal is an Advisory Board member at the Arizona State University program for Clinical Research Management and Regulatory Science, a member of the 8400-health network, and a Mass Challenge winner.

Throughout her career, Dr. Zafir-Lavie is seeking to use deep science and out-of-the-box thinking to promote translational work, which will prolong patients' lives. Dr. Zafir-Lavie is keen to promote technologies for improving women's health.